longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Hyperliquid Strategies

PURR

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 10.46, above the reasonable range, cheaper than 5.56% of the time in the past 1 years, and the industry ranks 27/602, the industry Median -2.44.

10.46xP/E
$13.55Stock price
$1.29Earnings per share
10.46xP/E
Stock price$13.55Earnings per share$1.29

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
8.83x
Typical range
5.89x–9.41x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.64x42.44%$5.06B
ACADUSAcadia Pharma
11.95x73.45%$4.55B
PURRUSHyperliquid Strategies
10.46x85.25%$2.68B
AUPHUSAurinia Pharma
7.04x54.40%$2.21B
ADMAUSAdma Biologics
12.60x35.42%$2.13B
LKFTUSLakefront Biotherapeutics
2.78x115.23%$1.93B
VORUSVor BioPharma
2.06x89.77%$1.30B
ABUSUSArbutus Pharma
6.43x533.09%$984.70M
RIGLUSRigel Pharma
2.73x83.91%$879.63M
BVNRYUSBavarian Nordic A/S
3.38x--$809.30M
IRWDUSIronwood Pharma
5.61x715.55%$728.71M
AGENUSAgenus
4.09x--$375.02M
QTTBUSQ32 Bio
9.23x162.23%$311.69M
CUVLUSClinuvel Pharmaceuticals
12.76x--$292.48M
CGENUSCompugen
6.55x173.68%$230.65M
PLXUSProtalix Biotherap
11.70x400.00%$221.57M
VXRTUSVaxart
3.10x328.57%$119.65M
RLYBUSRallybio
1.97x131.45%$89.91M
FBIOUSFortress Biotech
0.78x3,742.86%$80.38M
SPROUSSpero Therap
8.99x486.67%$66.39M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.